As third- or fourth-line therapy for patients with metastatic renal cell carcinoma (RCC), tivozanib hydrochloride demonstrated a statistically significant increased quality-adjusted time without symptoms of disease and toxicity (Q-TWiST) compared with sorafenib, according to data from (Nexavar) the phase 3 TIVO-3 trial (NCT02627963).1
“The difference in Q-TWiST in TIVO-3 was primarily driven by benefits of tivozanib in TWiST, partially offset by superiority of sorafenib in time after progression/relapse
[REL],” the investigators wrote in their abstract for the 2021 American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium.
To quantify the net health benefits of tivozanib, aVEGF tyrosine kinase inhibitor, the investigators applied Q-TWiST methods because of the similar survival of the 2 agents reported previously.2
Investigators calculated mean Q-TWiST by applying…